Welcome to our dedicated page for Relief Hldg news (Ticker: RLFTF), a resource for investors and traders seeking the latest updates and insights on Relief Hldg stock.
MindMaze Therapeutics Holding SA develops and commercializes precision digital treatments for neurological diseases and brain disorders. Its brain technology platform integrates software, proprietary sensors, telehealth, and AI-driven data analytics to support care from acute hospital treatment to outpatient and home-based therapy.
Company news covers FDA-cleared and CE-marked neurotherapeutics for areas such as stroke and Parkinson's disease, reimbursement strategy across healthcare systems, clinical validation, and R&D expansion into adjacent neurological indications. Updates also include the completed business combination that formed the MindMaze Therapeutics identity, along with shareholder voting, governance, capital-structure, and financial-reporting matters.
Relief Therapeutics Holding SA (OTCQB: RLFTF) announced that its U.S. partner, NRx Pharmaceuticals, has reported positive top-line data for ZYESAMI™ (RLF-100™/aviptadil) in highly comorbid COVID-19 patients. The treatment showed a threefold increase in one-year survival rates, consistent with prior phase 2b/3 trial results indicating enhanced 60-day survival rates. Relief focuses on clinical-stage therapies, with RLF-100™ targeting respiratory deficiencies due to COVID-19. The company also diversifies its pipeline through collaborations and recent acquisitions.
Relief Therapeutics Holding SA reported its half-year results for 2021, highlighting a focus on developing therapeutic products for severe diseases. The company has transformed into a multi-product, revenue-generating entity, primarily driven by the acquisition of APR Applied Pharma Research. Key developments include the filing of an NDA for ACER-001 and ongoing trials for RLF-100 (aviptadil), aimed at treating COVID-19 and other serious conditions. Despite a net loss of CHF 14.7 million, Relief maintains a strong cash position of CHF 40 million, positioning itself for strategic growth.
Relief Therapeutics announced positive findings regarding its PKU GOLIKE(R) product, developed by its subsidiary APR Applied Pharma Research. Data published in Nutrients suggests that the controlled release amino acid mix can reduce catabolic events in patients with phenylketonuria (PKU), enhancing amino acid utilization and improving quality of life. The product is recognized for its prolonged-release formulation which mimics natural protein absorption. Future clinical assessments are planned to support these findings, aiming for PKU GOLIKE(R) to become a prescription product in the U.S.
Relief Therapeutics announced on September 13, 2021, that it received scientific advice from the MHRA regarding its lead drug candidate, RLF-100 (aviptadil), aimed at treating respiratory deficiency in severe COVID-19 cases. The MHRA suggested a conditional marketing approval (CMA) pathway, allowing for early access to treatments. Relief also discussed the regulatory path with the EMA and indicated ongoing dialogue with the MHRA for necessary data from a Phase 2b/3 study conducted by NeuroRx. However, NeuroRx has yet to provide all required data, presenting potential risks.
Relief Therapeutics has announced the launch of PKU GOLIKE(R) KRUNCH, a chewable tablet designed for the dietary management of phenylketonuria (PKU), a rare genetic disorder affecting around 350,000 individuals globally. This new product aims to enhance patient adherence to therapy, providing a convenient 'on-the-go' option. The launch, taking place in Germany and Italy, leverages the Physiomimic Technology(TM) to offer a prolonged-release formulation that masks the product's unpleasant taste. Future expansion plans include additional markets across Europe.
Relief Therapeutics Holding AG (RLFTF) announced participation in the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. CFO Jack Weinstein will present a company overview, available on-demand starting September 13 at 7:00 AM ET on Relief's website. The presentation will be archived for 90 days. Relief focuses on clinical-stage programs, particularly RLF-100TM for COVID-19 respiratory deficiency. Additionally, Relief has collaborated with Acer Therapeutics on ACER-001 for treating Urea Cycle Disorders.
Relief Therapeutics (OTCQB: RLFTF) has responded to assertions made by NRx Pharmaceuticals in their September 3, 2021, Registration Statement. Relief disputes claims regarding the collaboration surrounding RLF-100 (aviptadil), specifically challenging accusations of misleading financial obligations and instability in the drug's formulation. Relief insists it has met all financial responsibilities and has requested transparency from NRx on clinical trial data and invoices. Relief also believes it can enforce its rights under the Collaboration Agreement if disputes remain unresolved.
Relief Therapeutics announced regulatory clearance for its subsidiary, AdVita Lifescience, to initiate a phase 2 clinical trial in Germany to evaluate inhaled aviptadil for treating sarcoidosis. This follows a proof-of-concept trial that showed potential benefits in 20 patients. The trial will be randomized, double-blind, and multicenter, focusing on alleviating sarcoidosis-related cough, which significantly impacts patient quality of life. This milestone supports Relief’s strategy of advancing treatment options for serious diseases with unmet needs.
Relief Therapeutics announced new findings from the phase 2b/3 trial of ZYESAMI (aviptadil) by its U.S. partner, NRx Pharmaceuticals, indicating significant improvements in blood oxygen levels in patients with acute respiratory failure due to COVID-19. This analysis may support NRx's application for Breakthrough Therapy Designation from the FDA, which could streamline the drug's pathway to market. Relief's collaboration with NRx aims to address the unmet needs in treating critically ill patients, enhancing its position in the biopharmaceutical landscape.
Relief Therapeutics (OTCQB: RLFTF) reported a safety update from NRx Pharmaceuticals regarding ZYESAMI(TM) (aviptadil) in the NIH-sponsored ACTIV-3 study. This drug is in late-stage clinical testing for respiratory deficiency due to COVID-19. Relief is also advancing its pipeline through a collaboration with Acer Therapeutics to develop ACER-001 for Urea Cycle Disorders. Recent acquisitions have diversified its portfolio, enhancing the company’s market position. Relief is committed to providing therapeutic relief from serious diseases.